

	<i>(Unaudited)</i>		<i>(Unaudited)</i>	
	For the three		For the nine	
	months ended		months end	
	September	September	September	September
	30, 2017	30, 2016	30, 2017	30, 2016
Net loss, as reported	\$ (386,858)	\$ (261,597)	\$ (2,195,156)	\$ (951,448)
Share based compensation expense	64,287	55,242	223,345	259,328
Depreciation and amortization	300,964	74,631	820,792	223,850
Interest Expense	164,915	3,274	218,032	10,511
Issuance of stock for compensation	-	-	336,000	-
Taxes	112,277	-	182,277	-
Adjusted EBITDA	<u>\$ 255,586</u>	<u>\$ (128,450)</u>	<u>\$ (414,710)</u>	<u>\$ (457,759)</u>

Forward-Looking Statements

Forward-Looking Statements. This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words "believe," "anticipate," "estimate," "expect," "intend," "plan," "project," "prospects," "outlook," and similar words or expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could" are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2016, including but not limited to the discussion under "Risk Factors" therein, which the Company has filed with the SEC and which may be viewed at <http://www.sec.gov>.

-- Financial Statement Schedules follow --

ICTV BRANDS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
AS OF

<u>ASSETS</u>	<u>September 30, 2017</u> <i>(Unaudited)</i>	<u>December 31, 2016</u>
CURRENT ASSETS:		
Cash and cash equivalents	\$ 961,024	\$ 1,390,641
Accounts receivable, net of \$428,533 and \$123,109, respectively	3,753,803	506,337
Inventories, net	7,479,842	1,499,270
Prepaid expenses and other current assets	352,678	254,303
Total current assets	12,547,347	3,650,551
Property and equipment	1,111,900	74,098
Less accumulated depreciation	(183,048)	(58,099)
Property and equipment, net	928,852	15,999
Intangibles assets, net	3,733,979	872,864
Total assets	\$ 17,210,178	\$ 4,539,414
<u>LIABILITIES AND SHAREHOLDERS' EQUITY</u>		
CURRENT LIABILITIES:		
Accounts payable and accrued liabilities	\$ 5,047,357	\$ 1,644,899
Current portion of long-term debt to related party	641,399	-
Deferred revenue	258,189	377,445
Deferred consideration	160,417	-
Other liabilities	369,563	288,525
Total current liabilities	6,476,925	2,310,869
Deferred revenue – long-term	215,077	274,374
Deferred consideration – long-term	1,026,097	-
Other liabilities – long-term	514,826	665,713
Long term debt to related party, net of current portion	1,298,863	-
Total long-term liabilities	2,983,193	940,087
COMMITMENTS AND CONTINGENCIES		
SHAREHOLDERS' EQUITY:		
Preferred stock 20,000,000 shares authorized, no shares issued and outstanding	-	-
Common stock, \$0.001 par value, 100,000,000 shares authorized, 52,324,032 and 28,343,007 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively	42,113	18,132
Additional paid-in-capital	19,970,657	11,546,804
Accumulated other comprehensive loss	208,924	-
Accumulated deficit	(12,471,634)	(10,276,487)
Total shareholders' equity	7,750,060	1,288,458
Total liabilities and shareholders' equity	\$ 17,201,178	\$ 4,539,414

See accompanying notes to the condensed consolidated financial statements as filed on www.sec.gov.

ICTV BRANDS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS and COMPREHENSIVE LOSS
(Unaudited)

	<u>For the three months ended</u>		<u>For the six months ended</u>	
	<u>September 30, 2017</u>	<u>September 30, 2016</u>	<u>September 30, 2017</u>	<u>September 30, 2016</u>
NET SALES	\$ 7,559,754	\$ 4,203,530	\$ 23,156,949	\$ 12,471,266
COST OF SALES	<u>3,049,989</u>	<u>1,158,998</u>	<u>7,995,170</u>	<u>3,698,764</u>
GROSS PROFIT	<u>4,509,765</u>	<u>3,044,532</u>	<u>15,161,779</u>	<u>8,772,502</u>
OPERATING EXPENSES:				
General and administrative	2,448,376	1,035,752	7,643,917	3,076,489
Selling and marketing	<u>4,102,346</u>	<u>2,267,103</u>	<u>11,346,321</u>	<u>6,636,950</u>
Total operating expenses	<u>6,590,722</u>	<u>3,302,855</u>	<u>18,990,238</u>	<u>9,713,439</u>
OPERATING LOSS	(2,080,957)	(258,323)	(3,828,459)	(940,937)
INTEREST EXPENSE, NET	(164,377)	(3,274)	(215,147)	(10,511)
GAIN ON SETTLEMENT	1,969,245	-	1,969,245	-
MISCELLANEOUS INCOME (LOSS)	<u>(130)</u>	<u>-</u>	<u>59,974</u>	<u>-</u>
LOSS BEFORE PROVISION FOR INCOME TAX	(274,581)	(261,597)	(2,012,879)	(951,448)
PROVISION FOR INCOME TAXES	<u>112,277</u>	<u>-</u>	<u>182,277</u>	<u>-</u>
NET LOSS	<u>\$ (386,858)</u>	<u>\$ (261,597)</u>	<u>\$ (2,195,156)</u>	<u>\$ (951,448)</u>
OTHER COMPREHENSIVE INCOME:				
Foreign currency translation adjustment	<u>112,223</u>	<u>-</u>	<u>208,924</u>	<u>-</u>
COMPREHENSIVE LOSS	<u>\$ (274,635)</u>	<u>\$ (261,597)</u>	<u>\$ (1,986,232)</u>	<u>\$ (951,448)</u>
NET LOSS PER SHARE				
BASIC	<u>\$ (0.01)</u>	<u>\$ (0.01)</u>	<u>\$ (0.04)</u>	<u>\$ (0.03)</u>
DILUTED	<u>\$ (0.01)</u>	<u>\$ (0.01)</u>	<u>\$ (0.04)</u>	<u>\$ (0.03)</u>
WEIGHTED AVERAGE NUMBER OF COMMON SHARES				
BASIC AND DILUTED	<u>52,321,826</u>	<u>28,202,739</u>	<u>49,518,478</u>	<u>28,184,584</u>

See accompanying notes to the condensed consolidated financial statements as filed on www.sec.gov.

ICTV BRANDS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017 AND 2016
(Unaudited)

	2017	2016
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net loss	\$ (2,195,156)	\$ (951,448)
Adjustments to reconcile net loss to net decrease in cash provided by (used in) operating activities:		
Depreciation	128,835	5,637
Amortization of intangible assets	691,957	218,213
Bad debt expense	903,710	693,607
Share based compensation	223,345	259,328
Issuance of stock for compensation	336,000	-
Change in fair value of contingent consideration	(48,035)	-
Loss on disposal of property and equipment	6,197	-
Noncash interest	105,459	11,933
Gain on settlement of contingent consideration	(1,969,245)	-
Change in assets and liabilities:		
Accounts receivable	(4,113,466)	(900,774)
Other receivable	(577,533)	-
Inventories	922,503	751,369
Prepaid expenses and other current assets	114,171	52,158
Accounts payable and accrued liabilities	3,603,242	(72,073)
Severance payable	-	(45,995)
Deferred revenue	(178,553)	82,304
Net cash provided by (used in) operating activities	(2,046,569)	104,259
CASH FLOWS FROM INVESTING ACTIVITIES:		
Acquisition of property and equipment	(171,196)	(1,290)
Cash paid for acquisition of PhotoMedex, Inc.	(5,000,000)	-
Net cash used in investing activities	(5,171,196)	(1,290)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds from issuance of common stock, net of costs	6,982,930	-
Proceeds from exercise of options	55,559	-
Payments of deferred consideration for acquisition	(14,583)	-
Payments of DermaWand asset purchase agreement	(150,000)	(225,000)
Repayments of long-term debt to related party	(87,441)	-
Net cash provided by (used in) financing activities	6,786,465	(225,000)
Effect of exchange rates on cash and cash equivalents	1,683	-
NET DECREASE IN CASH AND CASH EQUIVALENTS	(429,617)	(122,031)
CASH AND CASH EQUIVALENTS, beginning of the period	1,390,641	1,334,302
CASH AND CASH EQUIVALENTS, end of the period	\$ 961,024	\$ 1,212,271

SUPPLEMENTAL DISCLOSURE OF NON-CASH
ACTIVITY:

Cashless exercise of options	\$ 43	\$ -
Payments of DermaWand asset purchase agreement	\$ -	\$ 1,200,000
Acquisition of PhotoMedex on January 23, 2017		
Fair value of assets acquired	\$ 9,198,043	\$ -
Fair value of deferred consideration	(4,198,043)	-
Cash paid for acquisition	\$ 5,000,000	\$ -
Asset Acquisition of Ermis Labs on January 23, 2017		
Cost of assets acquired	\$ 1,981,822	\$ -
Present value of deferred consideration	(1,131,822)	-
Issuance of common stock for asset purchase	(850,000)	-
Cash paid for acquisition	\$ -	\$ -
Settlement of contingent consideration to PhotoMedex on July 12, 2017		
Contingent consideration owed to PhotoMedex	\$ 3,579,760	\$ -
Other receivables amount forgiven	(837,708)	-
Payables extinguished	1,017,193	-
Settlement amount in proceeds from long-term debt	(2,000,000)	-
Assignment of deposit amount	210,000	-
Gain on settlement of contingent consideration	\$ 1,969,245	\$ -

See accompanying notes to the condensed consolidated financial statements as filed on www.sec.gov.

Contact Information:

Rich Ransom

ransom@ictvbrands.com

484-598-2313

Ernest P. Kollias, Jr.

kollias@ictvbrands.com

484-598-2300